Ansell Valuation
Is ANN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ANN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ANN (A$32.71) is trading below our estimate of fair value (A$57.85)
Significantly Below Fair Value: ANN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ANN?
Key metric: As ANN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ANN's PE Ratio? | |
|---|---|
| PE Ratio | 40.2x |
| Earnings | US$76.50m |
| Market Cap | US$3.05b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 12.4x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does ANN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 44.2x | ||
NAN Nanosonics | 75.3x | 24.0% | AU$976.8m |
SDI SDI | 12x | 17.8% | AU$125.4m |
RHC Ramsay Health Care | 34.3x | 19.3% | AU$8.7b |
COH Cochlear | 55.3x | 11.7% | AU$19.7b |
ANN Ansell | 40.2x | 22.8% | AU$4.7b |
Price-To-Earnings vs Peers: ANN is good value based on its Price-To-Earnings Ratio (40.2x) compared to the peer average (44.2x).
Price to Earnings Ratio vs Industry
How does ANN's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 11 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: ANN is expensive based on its Price-To-Earnings Ratio (40.2x) compared to the Global Medical Equipment industry average (27.6x).
Price to Earnings Ratio vs Fair Ratio
What is ANN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 40.2x |
| Fair PE Ratio | 37.2x |
Price-To-Earnings vs Fair Ratio: ANN is expensive based on its Price-To-Earnings Ratio (40.2x) compared to the estimated Fair Price-To-Earnings Ratio (37.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | AU$32.71 | AU$32.35 -1.1% | 10.8% | AU$38.13 | AU$25.63 | n/a | 11 |
| Nov ’25 | AU$30.91 | AU$32.35 +4.6% | 10.8% | AU$38.13 | AU$25.63 | n/a | 11 |
| Oct ’25 | AU$32.17 | AU$30.80 -4.2% | 9.6% | AU$35.59 | AU$25.24 | n/a | 11 |
| Sep ’25 | AU$29.83 | AU$30.32 +1.6% | 9.5% | AU$34.82 | AU$24.87 | n/a | 11 |
| Aug ’25 | AU$27.48 | AU$28.26 +2.8% | 8.8% | AU$32.66 | AU$24.72 | n/a | 11 |
| Jul ’25 | AU$25.91 | AU$26.73 +3.2% | 10.7% | AU$31.92 | AU$22.20 | n/a | 12 |
| Jun ’25 | AU$24.45 | AU$26.80 +9.6% | 10.5% | AU$31.94 | AU$22.21 | n/a | 13 |
| May ’25 | AU$25.17 | AU$27.46 +9.1% | 10.4% | AU$32.66 | AU$22.78 | n/a | 13 |
| Apr ’25 | AU$24.58 | AU$25.23 +2.7% | 8.4% | AU$29.80 | AU$22.37 | n/a | 13 |
| Mar ’25 | AU$23.48 | AU$25.47 +8.5% | 8.3% | AU$30.08 | AU$22.59 | n/a | 13 |
| Feb ’25 | AU$24.09 | AU$24.89 +3.3% | 8.9% | AU$28.85 | AU$21.33 | n/a | 12 |
| Jan ’25 | AU$25.18 | AU$24.00 -4.7% | 9.3% | AU$28.41 | AU$20.16 | n/a | 11 |
| Dec ’24 | AU$23.54 | AU$24.52 +4.2% | 9.0% | AU$29.23 | AU$20.75 | n/a | 11 |
| Nov ’24 | AU$21.55 | AU$25.18 +16.8% | 9.1% | AU$29.95 | AU$21.26 | AU$30.91 | 11 |
| Oct ’24 | AU$22.13 | AU$25.31 +14.4% | 8.1% | AU$30.28 | AU$21.53 | AU$32.17 | 11 |
| Sep ’24 | AU$23.42 | AU$26.21 +11.9% | 9.7% | AU$31.32 | AU$21.62 | AU$29.83 | 12 |
| Aug ’24 | AU$24.35 | AU$26.19 +7.6% | 10.3% | AU$30.94 | AU$22.62 | AU$27.48 | 12 |
| Jul ’24 | AU$26.73 | AU$27.57 +3.1% | 8.5% | AU$30.42 | AU$23.85 | AU$25.91 | 13 |
| Jun ’24 | AU$27.07 | AU$28.44 +5.1% | 8.5% | AU$31.95 | AU$24.77 | AU$24.45 | 13 |
| May ’24 | AU$26.85 | AU$27.25 +1.5% | 8.7% | AU$30.79 | AU$23.87 | AU$25.17 | 12 |
| Apr ’24 | AU$26.53 | AU$26.89 +1.3% | 7.8% | AU$30.37 | AU$23.61 | AU$24.58 | 12 |
| Mar ’24 | AU$27.29 | AU$26.89 -1.5% | 7.8% | AU$30.37 | AU$23.61 | AU$23.48 | 12 |
| Feb ’24 | AU$27.98 | AU$27.91 -0.3% | 10.2% | AU$31.89 | AU$22.31 | AU$24.09 | 12 |
| Jan ’24 | AU$28.24 | AU$28.86 +2.2% | 10.6% | AU$33.33 | AU$23.80 | AU$25.18 | 12 |
| Dec ’23 | AU$28.77 | AU$28.82 +0.2% | 10.3% | AU$33.13 | AU$23.66 | AU$23.54 | 12 |
| Nov ’23 | AU$28.55 | AU$30.42 +6.5% | 9.5% | AU$35.22 | AU$24.67 | AU$21.55 | 12 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
SDI
AU$122.4m
Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.
SDI
AU$1.03
7D
-4.2%
1Y
30.4%
CardieX
AU$30.9m
Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.
CDX
AU$0.10
7D
-22.2%
1Y
n/a
Nova Eye Medical
AU$34.4m
Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.
EYE
AU$0.15
7D
1.7%
1Y
17.3%